| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00535-010-0278-5 |
| P698 | PubMed publication ID | 20625772 |
| P50 | author | Kiyoshi Hasegawa | Q88313572 |
| Yasuhiko Sugawara | Q88725880 | ||
| Taku Aoki | Q88726675 | ||
| Norihiro Kokudo | Q88727177 | ||
| Hitoshi Ikeda | Q90470714 | ||
| Yutaka Matsuyama | Q90878247 | ||
| Yoshifumi Beck | Q114433482 | ||
| Kentaroh Yamamoto | Q114433523 | ||
| P2093 | author name string | Gary L Norman | |
| Yukio Kume | |||
| Hiroshi Imamura | |||
| Zakera Shums | |||
| P2860 | cites work | Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients | Q28201418 |
| Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma | Q28262901 | ||
| Management of hepatocellular carcinoma | Q29616230 | ||
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis | Q33413505 | ||
| Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial | Q33920539 | ||
| The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma | Q34162174 | ||
| The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population | Q34577896 | ||
| PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. | Q34726807 | ||
| Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases | Q34879929 | ||
| Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma | Q35621312 | ||
| Hepatocellular carcinoma: recent trends in the United States | Q35929212 | ||
| Serological markers of liver cancer. | Q36066450 | ||
| Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan | Q37014868 | ||
| Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma | Q37246570 | ||
| Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. | Q37577551 | ||
| Basic principles of ROC analysis | Q39680201 | ||
| Surgery for small liver cancers | Q40766743 | ||
| Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma | Q44369910 | ||
| Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis | Q44930765 | ||
| Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size | Q47329577 | ||
| GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population | Q47927175 | ||
| Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. | Q51765488 | ||
| Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462). | Q53504437 | ||
| Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC | Q57763607 | ||
| Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma | Q68948227 | ||
| Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein | Q71621986 | ||
| Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma | Q71659274 | ||
| Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis | Q72073556 | ||
| A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma | Q72101788 | ||
| Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone | Q74471419 | ||
| Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma | Q74623798 | ||
| Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma | Q78167282 | ||
| Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers | Q79390690 | ||
| Clinicopathologic features of poorly differentiated hepatocellular carcinoma | Q79839804 | ||
| Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma | Q80213441 | ||
| GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma | Q81152245 | ||
| Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma | Q81926268 | ||
| Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy | Q84383842 | ||
| P433 | issue | 12 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1272-1282 | |
| P577 | publication date | 2010-07-13 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC | |
| P478 | volume | 45 |
| Q64272871 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
| Q91599660 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
| Q37177443 | A Chemiluminescent Protein Microarray Method for Determining the Seroglycoid Fucosylation Index |
| Q36298291 | A novel core fucose-specific lectin from the mushroom Pholiota squarrosa. |
| Q98771230 | A-G Score Associated With Outcomes in Solitary Hepatocellular Carcinoma Patients After Hepatectomy |
| Q35206309 | Aberrant glycosylation associated with enzymes as cancer biomarkers |
| Q37738102 | Aided Diagnosis of Hepatocellular Carcinoma Using Serum Fucosylated Haptoglobin Ratios |
| Q36082480 | Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again |
| Q26799462 | Biological features and biomarkers in hepatocellular carcinoma |
| Q33913585 | Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy |
| Q28080175 | Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma |
| Q91597204 | Clinical Features and Surveillance of Very Late Hepatocellular Carcinoma Recurrence After Liver Transplantation |
| Q38980072 | Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma |
| Q41859517 | Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma |
| Q37351966 | Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy |
| Q51055149 | Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels. |
| Q37122823 | Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. |
| Q36261800 | Diagnostic value of serum Golgi protein 73 for HBV-related primary hepatic carcinoma |
| Q92092492 | Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies |
| Q35062428 | Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis |
| Q38438798 | Expression pattern analysis of hepatocellular carcinoma tumor markers in viral hepatitis B and C patients undergoing liver transplantation and resection |
| Q41431029 | Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
| Q93348073 | Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches |
| Q38366329 | Glycosylation and liver cancer |
| Q91889025 | Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of survivin promoter-driven HSVtk in hepatocellular carcinoma |
| Q57809722 | Golgi protein 73 and its diagnostic value in liver diseases |
| Q37975644 | Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis |
| Q29048613 | Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels |
| Q34550662 | Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma |
| Q47552123 | Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells. |
| Q34233955 | Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. |
| Q37694786 | Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression |
| Q89083657 | Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases |
| Q39528390 | MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. |
| Q40570164 | Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases |
| Q33584901 | Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis |
| Q51457860 | Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients. |
| Q35753801 | Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma |
| Q38155289 | Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation |
| Q35110831 | Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. |
| Q41565833 | Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma |
| Q42319947 | Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis. |
| Q64235731 | Studying the Impact of Golgi Protein 73 Serving as a Candidate Biomarker in Early Diagnosis for Hepatocellular Carcinoma among Saudi Patients |
| Q92881310 | TUG1 Is a Regulator of AFP and Serves as Prognostic Marker in Non-Hepatitis B Non-Hepatitis C Hepatocellular Carcinoma |
| Q47278009 | The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review |
| Q34428389 | The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review |
| Q37943714 | The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC). |
| Q40644252 | The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics |
| Q89695747 | The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis |
| Q27016138 | Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. |
| Q37363484 | Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study |
| Q84449015 | Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival |
| Q24608195 | Tumor markers for hepatocellular carcinoma (Review) |
| Q51063243 | Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. |
| Q36715087 | Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma |
| Q33906226 | Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease |
Search more.